awmsg logo



recombinant L-asparaginase (Spectrila®)


Reference No. 2968

Publication date:
03/05/2016


Appraisal information

recombinant L-asparaginase (Spectrila®) 10 000 U powder for concentrate for solution for infusion


Company: medac GmbH
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/04/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, asparaginase (Spectrila®) cannot be endorsed for use within NHS Wales as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia in paediatric patients from birth to 18 years and adult patients.
Statement of Advice (SOA)
Download